Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Boris Waldman"'
Autor:
James C. Weaver, Bruce Cartwright, Boris Waldman, Anthony C Keech, David D'Silva, Michael Byrom
Publikováno v:
Journal of Cardiothoracic and Vascular Anesthesia. 35:910-913
Left ventricular free wall rupture is a feared complication of myocardial infarction and revascularization therapies. Transesophageal echocardiography (TEE) has an established role in cardiac surgery and a growing role in percutaneous intracardiac pr
Publikováno v:
The AustralianNew Zealand journal of obstetricsgynaecologyReferences. 61(1)
Background Induction of labour (IOL) and caesarean section (CS) rates continue to increase in Australia, New Zealand and globally. There is evidence that CS rates are decreased in the context of medically indicated and elective IOL; therefore, the em
Autor:
Russell S. Scott, Ian C. Marschner, Nanda R. Aryal, Neil McGill, Anthony C Keech, Alicia J. Jenkins, Taskinen, RJ Simes, Boris Waldman, Sullivan, Jy Cao, Val Gebski, Rachel O'Connell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72eee9fd9638aef622d99f806bea7927
https://doi.org/10.1111/dom.14046/v2/response1
https://doi.org/10.1111/dom.14046/v2/response1
Publikováno v:
A&A Practice. 16:e01562
Autor:
Russell S. Scott, Philip J. Barter, David R. Sullivan, Alicia J. Jenkins, Andrzej S. Januszewski, Kerry-Anne Rye, Kwok Leung Ong, Anthony C Keech, John Simes, Aimin Xu, Rachel O'Connell, Marja-Riitta Taskinen, James D. Best, Boris Waldman, Peter G. Colman
Publikováno v:
Clinical Chemistry. 63:1261-1270
BACKGROUND It is not known whether circulating fibroblast growth factor 21 (FGF21) concentrations are associated with glycemic progression in patients with established type 2 diabetes. This study reports this relationship in type 2 diabetes patients
Autor:
Ian C. Marschner, Boris Waldman, Anthony C Keech, John Simes, Jacob Y. Cao, David R. Sullivan, Nanda R. Aryal, Field investigators, Alicia J. Jenkins, Neil McGill, Val Gebski, Russell S. Scott, Rachel O'Connell, Marja-Riitta Taskinen
Publikováno v:
Diabetes, obesitymetabolismREFERENCES. 22(8)
Aim To explore the relationship between baseline uric acid (UA) levels and long-term cardiovascular events in adults with type 2 diabetes (T2D) and to determine whether the cardioprotective effects of fenofibrate are partly mediated through its UA-lo
Autor:
Jacob Y. Cao, Boris Waldman, Val Gebski, Anthony C Keech, Rachel O'Connell, R. John Simes, Alicia J. Jenkins, David R. Sullivan, Marja-Riitta Taskinen, Russell S. Scott, Neil McGill, Ian C. Marschner, Andrzej S. Januszewski
Publikováno v:
Diabetes. 68
Background: Fenofibrate increases renal clearance of uric acid (UA). Relationships between baseline and short-term changes in plasma UA with fenofibrate and subsequent cardiovascular risk in patients with type 2 diabetes (T2D) are unknown. Method: Po
Autor:
M.-R. Taskinen, Val Gebski, Alicia J. Jenkins, Rachel O'Connell, Anthony C Keech, Neil McGill, Russell S. Scott, Boris Waldman, John Simes, Ian C. Marschner, J. Cao, David R. Sullivan
Publikováno v:
Heart, Lung and Circulation. 28:S286-S287
Autor:
Boris Waldman, Val Gebski, Christelle Foucher, David R. Sullivan, Luke Buizen, Alicia J. Jenkins, Anthony C Keech, Timothy M. E. Davis, Liping Li, Russell S. Scott, Michael D. Feher, Y. Antero Kesäniemi, Jean-Claude Ansquer, Jeff R. Flack, Michael C d'Emden, Neil McGill, James D. Best, John D. Hedley
Publikováno v:
The lancet. Diabetesendocrinology. 6(4)
Gout is a painful disorder and is common in type 2 diabetes. Fenofibrate lowers uric acid and reduces gout attacks in small, short-term studies. Whether fenofibrate produces sustained reductions in uric acid and gout attacks is unknown.In the Fenofib
Autor:
Gulnara N, Rakhimova, Nasiba U, Alimova, Alexsandr, Ryaboshtan, Boris, Waldman, Graham D, Ogle, Said I, Ismailov
Publikováno v:
Pediatric diabetes. 19(1)
We aimed to determine the incidence, prevalence and mortality of type 1 diabetes (T1D) in Uzbekistan in children15 years old.In a prospective study from 1998 to 2014 the primary ascertainment of incidence, prevalence and mortality, and cause of death